One gene, many phenotypes

Journal of Postgraduate Medicine

Volumn 53, Issue 4, 2007, Pages 257-261

  Prasun, P ^a   Pradhan, M ^a   Agarwal, S ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Genotype; Genotype phenotype correlation; Phenotype

Indexed keywords

GENE PRODUCT;

ALLELE; BETA THALASSEMIA; DNA MODIFICATION; EPIGENETICS; GENE DOSAGE; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; GENOME IMPRINTING; HUMAN; MEDICAL PRACTICE; MEDICAL RESEARCH; MOSAICISM; PHENOTYPE; PROTEOMICS; REVIEW; RNA SPLICING; RNA TRANSLATION; SICKLE CELL ANEMIA; SPINAL MUSCULAR ATROPHY; X CHROMOSOME INACTIVATION;

EID: 37848999364     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: 10.4103/0022-3859.33968     Document Type: Review

References (56)

1. Hassoun H, Vassiliadis JN, Murray J, Njolstad PR, Rogus JJ, Ballas SK, et al. Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. Blood 1997;90:398-406.
2. Nakanishi H, Kanzaki A, Yawata A, Yamada O, Yawata Y. Ankyrin gene mutations in Japanese patients with hereditary spherocytosis. Int J Hematol 2001;73:54-63.
3. Yawata Y, Kanzaki A, Yawata A, Doerfler W, Ozcan R, Eber SW. Characteristic features of the genotype and phenotype of hereditary spherocytosis in the Japanese population. Int J Hematol 2000;71:118-35.
4. Bolton-Maggs PH. Hereditary spherocytosis: New guidelines. Arch Dis Child 2004;89:809-12.
5. Dork T, Dworniczak B, Aulehla-Scholz C, Wieczorek D, Bohm I, Mayerova A, et al. Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. Hum Genet 1997;100:365-77.
6. Mickle JE, Cutting GR. Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am 2000;84:597-607.
7. Radpour R, Gilani MA, Gourabi H, Dizaj AV, Mollamohamadi S. Molecular analysis of the IVS8-T splice variant 5T and M470V exon 10 missense polymorphism in Iranian males with congenital bilateral absence of the vas deferens. Mol Hum Reprod 2006;12:469-73.
8. Quinn CT, Miller ST. Risk factors and prediction of outcomes in children and adolescents who have sickle cell anemia. Hematol Oncol Clin North Am 2004;18:1339-54.
9. Meschia JF, Pankratz VS. Defining stroke risks in sickle cell anemia. Nat Genet 2005;37:340-1.
10. Hayward P. Genetic model predicts stroke in sickle-cell disease. Lancet Neurol 2005;4:277.
11. Adams GT, Snieder H, McKie VC, Clair B, Brambilla D, Adams RJ, et al. Genetic risk factors for cerebrovascular disease in children with sickle cell disease: Design of a case-control association study and genomewide screen. BMC Med Genet 2003;4:6.
12. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000;342:83-9.
13. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood 2004;103:4023-7.
14. Steinberg MH, Dreiling BJ, Morrison FS, Necheles TF. Mild sickle cell disease. Clinical and laboratory studies. JAMA 1973;224:317-21.
15. Strachan T, Read AP. Human molecular genetics. John Wiley and Sons (Asia) Pvt Ltd: Singapore; 1999.
16. Simpson RJ. Proteins and proteomics: A laboratory manual. Cold Spring Harbor Laboratory Press: New York; 2003.
17. Azad NS, Rasool N, Annunziata CM, Minasian L, Whiteley G, Kohn EC. Proteomics in clinical trials and practice: present uses and future promise. Mol Cell Proteomics 2006;5:1819-29.
18. Leibler CD, Yates RJ. Introduction to proteomics: Tools for the new biology. Humana Press: Totowa, NJ; 2002.
19. Ge H, Walhout AJ, Vidal M. Integrating 'omic' information: A bridge between genomics and systems biology. Trends Genet 2003;19:551-60.
20. Dode C, Levilliers J, Dupont JM, De Paepe A, Le Du N, Soussi-Yanicostas N, et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 2003;33:463-5.
21. Muenke M, Schell U. Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet 1995;11:308-13.
22. Youssoufian H, Pyeritz RE. Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet 2002;3:748-58.
23. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 2003;348:2656-68.
24. McShane MA, Hammans SR, Sweeney M, Holt IJ, Beattie TJ, Brett EM, et al. Pearson syndrome and mitochondrial encephalomyopathy in a patient with a deletion of mtDNA. Am J Hum Genet 1991;48:39-42.
25. Holterhus PM, Bruggenwirth HT, Hiort O, Kleinkauf-Houcken A, Kruse K, Sinnecker GH, et al. Mosaicism due to a somatic mutation of the androgen receptor gene determines phenotype in androgen insensitivity syndrome. J Clin Endocrinol Metab 1997;82:3584-9.
26. Kohler B, Lumbroso S, Leger J, Audran F, Grau ES, Kurtz F, et al. Androgen insensitivity syndrome: Somatic mosaicism of the androgen receptor in seven families and consequences for sex assignment and genetic counseling. J Clin Endocrinol Metab 2005;90:106-11.
27. Gottlieb B, Beitel LK, Trifiro MA. Somatic mosaicism and variable expressivity. Trends Genet 2001;17:79-82.
28. Boehmer AL, Brinkmann AO, Niermeijer MF, Bakker L, Halley DJ, Drop SL. Germ-line and somatic mosaicism in the androgen insensitivity syndrome: Implications for genetic counseling. Am J Hum Genet 1997;60:1003-6.
29. Nadeau JH. Modifier genes in mice and humans. Nat Rev Genet 2001;2:165-74.
30. Thein SL. Genetic insights into the clinical diversity of beta thalassaemia. Br J Haematol 2004;124:264-74.
31. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: Lessons from the thalassaemias. Nat Rev Genet 2001;2:245-55.
32. Dover GJ, Smith KD, Chang YC, Purvis S, Mays A, Meyers DA, et al. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood 1992;80:816-24.
33. Craig JE, Rochette J, Fisher CA, Weatherall DJ, Marc S, Lathrop GM, et al. Dissecting the loci controlling fetal haemoglobin production on chromosomes 11p and 6q by the regressive approach. Nat Genet 1996;12:58-64.
34. Garner CP, Tatu T, Best S, Creary L, Thein SL. Evidence of genetic interaction between the beta-globin complex and chromosome 8q in the expression of fetal hemoglobin. Am J Hum Genet 2002;70:793-9.
35. Steinberg MH, Rodgers GP. Pathophysiology of sickle cell disease: Role of cellular and genetic modifiers. Semin Hematol 2001;38:299-306.
36. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005;37:435-40.
37. Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol 2005;129:465-81.
38. Steinberg MH, Rosenstock W, Coleman MB, Adams JG, Platica O, Cedeno M, et al. Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia. Blood 1984;63:1353-60.
39. Wirth B, Brichta L, Schrank B, Lochmuller H, Blick S, Baasner A, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet 2006;119:422-8.
40. Ma SK, Au WY, Chan AY, Chan LC. Clinical phenotype of triplicated alpha-globin genes and heterozygosity for beta-thalassemia in Chinese subjects. Int J Mol Med 2001;8:171-5.
41. Traeger-Synodinos J, Kanavakis E, Vrettou C, Maragoudaki E, Michael T, Metaxotou-Mavromati A, et al. The triplicated alpha-globin gene locus in beta-thalassaemia heterozygotes: Clinical, haematological, biosynthetic and molecular studies. Br J Haematol 1996;95:467-71.
42. Camaschella C, Kattamis AC, Petroni D, Roetto A, Sivera P, Sbaiz L, et al. Different hematological phenotypes caused by the interaction of triplicated alpha-globin genes and heterozygous beta-thalassemia. Am J Hematol 1997;55:83-8.
43. Chelly J, Gilgenkrantz H, Lambert M, Hamard G, Chafey P, Recan D, et al. Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies. Cell 1990;63:1239-48.
44. Disset A, Bourgeois CF, Benmalek N, Claustres M, Stevenin J, Tuffery-Giraud S. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements. Hum Mol Genet 2006;15:999-1013.
45. Shiga N, Takeshima Y, Sakamoto H, Inoue K, Yokota Y, Yokoyama M, et al. Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy. J Clin Invest 1997;100:2204-10.
46. Kiesewetter S, Macek M Jr, Davis C, Curristin SM, Chu CS, Graham C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet 1993;5:274-8.
47. Massie RJ, Poplawski N, Wilcken B, Goldblatt J, Byrnes C, Robertson C. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. Eur Respir J 2001;17:1195-200.
48. Lissens W, Mahmoud KZ, El-Gindi E, Abdel-Sattar A, Seneca S, Van Steirteghem A, et al. Molecular analysis of the cystic fibrosis gene reveals a high frequency of the intron 8 splice variant 5T in Egyptian males with congenital bilateral absence of the vas deferens. Mol Hum Reprod 1999;5:10-3.
49. Jezequel P, Dorval I, Fergelot P, Chauvel B, Le Treut A, Le Gall JY, et al. Structural analysis of CFTR gene in congenital bilateral absence of vas deferens. Clin Chem 1995;41:833-5.
50. Dork T, Dworniczak B, Aulehla-Scholz C, Wieczorek D, Bohm I, Mayerova A, et al. Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. Hum Genet 1997;100:365-77.
51. Landers M, Bancescu DL, Le Meur E, Rougeulle C, Glatt-Deeley H, Brannan C, et al. Regulation of the large (approximately 1000 kb) imprinted murine Ube3a antisense transcript by alternative exons upstream of Snurf/Snrpn. Nucl Acids Res 2004;32:3480-92.
52. Nicholls RD, Saitoh S, Horsthemke B. Imprinting in Prader-Willi and Angelman syndromes. Trends Genet 1998;14:194-200.
53. Glenn CC, Driscoll DJ, Yang TP, Nicholls RD. Genomic imprinting: Potential function and mechanisms revealed by the Prader-Willi and Angelman syndromes. Mol Hum Reprod 1997;3:321-32.
54. Clayton-Smith J, Laan L. Angelman syndrome: A review of the clinical and genetic aspects. J Med Genet 2003;40:87-95.
55. Malzac P, Webber H, Moncla A, Graham JM, Kukolich M, Williams C, et al. Mutation analysis of UBE3A in Angelman syndrome patients. Am J Hum Genet 1998;62:1353-60.
56. Lyonnet S, Feingold J, Frezal J. Genotype-phenotype relationships. In: Cooper DN, editor. Nature encyclopedia of human genome. Nature Publishing Group: London; 2003. p. 56-63.